| Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599 IE Stewart, PB Lukka, J Liu, B Meibohm, M Gonzalez-Juarrero, ... Pharmaceutical research 36, 1-13, 2019 | 28 | 2019 |
| X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin … S Banerjee, F Mahmud, S Deng, L Ma, MK Yun, SO Fakayode, KE Arnst, ... Journal of medicinal chemistry 64 (17), 13072-13095, 2021 | 18 | 2021 |
| Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells NM Midde, N Sinha, PB Lukka, B Meibohm, S Kumar PloS one 12 (2), e0172628, 2017 | 16 | 2017 |
| Preclinical evaluation of inhalational spectinamide-1599 therapy against tuberculosis M Gonzalez-Juarrero, PB Lukka, S Wagh, A Walz, J Arab, C Pearce, Z Ali, ... ACS infectious diseases 7 (10), 2850-2863, 2021 | 15 | 2021 |
| Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor Z Wu, L Gu, S Zhang, T Liu, PB Lukka, B Meibohm, JC Bollinger, M Zhou, ... Journal of medicinal chemistry 64 (4), 1930-1950, 2021 | 14 | 2021 |
| Use of real‐world data and pharmacometric modeling in support of lacosamide dosing in pediatric patients under 4 years of age PB Lukka, M Woods, R Chhim, SJ Phelps, JW Wheless, B Meibohm The Journal of Clinical Pharmacology 61 (7), 881-888, 2021 | 13 | 2021 |
| Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis S Wagh, C Rathi, PB Lukka, K Parmar, Z Temrikar, J Liu, MS Scherman, ... Antimicrobial agents and chemotherapy 65 (11), 10.1128/aac. 01744-20, 2021 | 12 | 2021 |
| Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice C Rathi, PB Lukka, S Wagh, RE Lee, AJ Lenaerts, M Braunstein, A Hickey, ... Tuberculosis 114, 119-122, 2019 | 12 | 2019 |
| Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo … S Altrichter, AM Giménez-Arnau, JA Bernstein, M Metz, L Bahadori, ... British Journal of Dermatology, ljae067, 2024 | 10 | 2024 |
| Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice PB Lukka, JW Paxton, P Kestell, BC Baguley Cancer chemotherapy and pharmacology 65, 1145-1152, 2010 | 10 | 2010 |
| A rapid LC–MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development PB Lukka, JW Paxton, GJ Atwell, P Kestell, BC Baguley Journal of pharmaceutical and biomedical analysis 63, 9-16, 2012 | 9 | 2012 |
| Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study) HJ Wedner, T Fujisawa, TW Guilbert, M Ikeda, V Mehta, JS Tam, ... Pediatric Allergy and Immunology 35 (3), e14092, 2024 | 8 | 2024 |
| Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer S Deng, RI Krutilina, KL Hartman, H Chen, DN Parke, R Wang, F Mahmud, ... Molecular cancer therapeutics 21 (7), 1103-1114, 2022 | 8 | 2022 |
| Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent YY Chen, PB Lukka, WR Joseph, GJ Finlay, JW Paxton, MJ McKeage, ... Cancer chemotherapy and pharmacology 74, 25-35, 2014 | 8 | 2014 |
| Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics PB Lukka, JW Paxton, P Kestell, BC Baguley Cancer chemotherapy and pharmacology 70, 151-160, 2012 | 8 | 2012 |
| Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis K Santos, PB Lukka, A Grzegorzewicz, M Jackson, A Trivedi, F Pavan, ... Frontiers in Microbiology 9, 1895, 2018 | 7 | 2018 |
| Development and validation of a liquid chromatography–mass spectrometry (LC–MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino) ethyl]-2, 6-dimethyl-1 … PB Lukka, P Kestell, JW Paxton, BC Baguley Journal of Chromatography B 875 (2), 368-372, 2008 | 7 | 2008 |
| Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus GA Phelps, MN Cheramie, DM Fernando, P Selchow, CJ Meyer, ... Proceedings of the National Academy of Sciences 121 (2), e2314101120, 2024 | 6 | 2024 |
| Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent PB Lukka, YY Chen, GJ Finlay, WR Joseph, E Richardson, JW Paxton, ... Cancer chemotherapy and pharmacology 72, 1013-1022, 2013 | 5 | 2013 |
| Efficacy of a brain-penetrant antiviral in lethal Venezuelan and eastern equine encephalitis mouse models X Cao, D Yang, J Parvathareddy, Y Chu, EJ Kim, JN Fitz-Henley, X Li, ... Science Translational Medicine 15 (691), eabl9344, 2023 | 4 | 2023 |
SANTOSH WAGHAssociate Director, Clinical Pharmacology, Pfizer在 pfizer.com 的电子邮件经过验证
